Samsung BioLogics seals coveted $2bn IPO

Jonathan Breen

October 28, 2016 07:45 am

korea px230 — Members of a "Samulnori" dance troupe, or traditional South Korean percussion quartet, perform during the inauguration of South Korea's new President Park Geun-hye, not pictured, at parliament in Seoul, South Korea, Monday, Feb. 25, 2013. Elected in December, Park is believed to be the first Korean woman to rule in a millennium. (AP Photo/Kim Hong-Ji, Pool) | Kim Hong-Ji/AP/Press Association Images

Samsung BioLogics Co has priced its IPO at the top on the back of a surge in chunky orders, raising W2.25tr ($2.0bn) in South Korea's largest float since 2010.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login

✔ 4,000 annual insights
✔ 700+ notes and long-form analyses
✔ 4 capital markets databases
✔ Daily newsletters across markets and asset classes
✔ 2 weekly podcasts

Topics

JP Morgan Credit Suisse Equity IPOs Equity Korea Investment and Securities Citi South Korea Asia Northeast Asia Asia Pacific Emerging Markets

JB

Jonathan Breen

Equities editor GlobalCapital Asia